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Abstract In a porcine model of cardiopulmonary resuscitation
(CPR), we investigated changes in the plasma levels of 8-iso-
PGF2K, a marker for oxidative injury, and 15-keto-dihydro-
PGF2K, an inflammatory response indicator during the post-
resuscitation period after cardiac arrest. Twelve piglets were
subjected to either 2 or 5 min (VF2 and VF5 group) of ventricular
fibrillation (VF) followed by 5 min of closed-chest CPR. Six
piglets without cardiac arrest were used as controls. In VF5
group, 8-iso-PGF2K in the jugular bulb plasma (draining the
brain) increased four-fold. Jugular bulb 8-iso-PGF2K in the
control group remained unchanged. The 15-keto-dihydro-PGF2K
also increased four-fold in the VF5 group. Thus, 8-iso-PGF2K
and 15-keto-dihydro-PGF2K measurements in jugular bulb
plasma may be used as biomarkers for quantification of free
radical catalyzed oxidative brain injury and inflammatory
response in reperfusion injury.
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1. Introduction
Neurologic outcome after cardiac arrest remains poor.
Complicating post-ischemic disturbances could contribute to
poor neurologic recovery after circulatory arrest [1]. Oxidative
stress caused by lipid or protein oxidation through intracellu-
lar free radical generation may aggravate a perturbed mem-
brane function and mitochondrial dysfunction and is believed
to contribute to the reperfusion injury [2,3]. Furthermore,
local in£ammatory mechanisms including the release of cyto-
kines, an upregulation of cell adhesion molecule expression
and the subsequent induction of leukocyte accumulation
could aggravate the microvascular dysfunction after ischemia
[4] and may, therefore, impair the potential for neurologic
recovery after circulatory arrest.
A problem related to the assessment of reperfusion injury
has been the limitation in available methods for in vivo mea-
surement of free radical generation or end products of free
radical catalyzed oxidation of lipids [5]. In 1990, Morrow et
al. reported the discovery of isoprostanes, a new family of
prostaglandin derivatives biosynthesized in vivo through
non-enzymatic free radical catalyzed oxidation of arachidonic
acid [6]. It has also been observed that one of the major
isoprostanes, 8-iso-prostaglandin F2K (8-iso-PGF2K, Fig. 1) is
increased in several syndromes that are supposed to be asso-
ciated with oxidant injury and the measurement of isopros-
tanes can be used as a reliable method for in vivo measure-
ment of oxidant injury [7^14].
Cyclooxygenase-2 (COX-2), an isoform of cyclooxygenase,
has been shown to be expressed in macrophages, epithelial
cells and ¢broblasts by several pro-in£ammatory stimuli
(cytokines, growth factors), leading to the release of pros-
taglandins (Fig. 1) [15^17]. 15-Keto-13,14-dihydro-PGF2K,
a major metabolite of prostaglandin F2K, is increased in in-
£ammatory response and can be used as an indicator for in
vivo lipid peroxidation through the cyclooxygenase pathway
[18].
We have recently developed highly speci¢c and sensitive
radioimmunoassays (RIA) by raising unique antibodies in
rabbits against both 8-iso-PGF2K (indicating oxidative injury)
and 15-keto-dihydro-PGF2K (indicating in£ammatory re-
sponse) [18,19]. The antibodies discriminate these two very
closely related substances. By applying these parameters, we
have shown that oxidative modi¢cation of arachidonic acid
through both non-enzymatic and enzymatic pathways is in-
volved in endotoxin induced in£ammation and hepatotoxin
induced oxidative injury as demonstrated by signi¢cantly in-
creased formation of F2-isoprostane and PGF2K metabolite in
plasma and urine [10,12,14]. These results suggest that oxida-
tive injury and in£ammation are closely associated in various
syndromes, and could be involved in the pathogenesis of other
free radical mediated diseases.
In the present study, oxidative injury and in£ammatory
response in the brain after resuscitation from circulatory ar-
rest were investigated by the measurement of 8-iso-PGF2K and
15-keto-dihydro-PGF2K, in plasma collected from the superior
bulb of the internal jugular vein (jugular bulb), a direct con-
tinuation of the sigmoid sinus which drains the brain. Simul-
taneous measurement of F2-isoprostane and prostaglandin
metabolite in pulmonary arterial blood samples (mixed ve-
nous blood from the superior and inferior vena cava and
the coronary sinus) provides further information about sys-
temic oxidative reperfusion injury and in£ammation, respec-
tively.
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2. Materials and methods
2.1. Chemicals
Unlabelled 8-iso-PGF2K, 15-K-DH-PGF2K and other related iso-
prostanes and prostaglandins were purchased from Cayman Chemi-
cals, Ann Arbor, MI, USA. The tritium labelled 8-iso-PGF2K (speci¢c
activity: 608 GBq mmol31) was synthesized and puri¢ed as described
previously [19]. The tritium labelled 15-K-DH-PGF2K (speci¢c activ-
ity: 6.77 TBq mmol31) was obtained from Amersham (Buckingham-
shire, UK). Antibodies against both 8-iso-PGF2K and 15-K-DH-
PGF2K were raised at our laboratory and are well characterized
[18,19].
2.2. Animal preparation
The animal experiments were approved by the Animal Ethical
Committee, Uppsala University, Sweden and in accordance with a
well established protocol from our laboratory [20]. Eighteen Swedish
breed piglets of both gender, 11^15 weeks of age and with a mean
weight of 24 þ 1 kg were used. Catheters were inserted via a branch of
the right external carotid artery into the aortic arch for pressure
monitoring, and via the right external jugular vein into a branch of
pulmonary artery for blood sampling. A catheter was also inserted
into the right atrium for drug administration and another catheter (20
Gauge) was inserted into the left internal jugular vein and passed
retrogradely into the jugular bulb for blood sampling.
2.3. Experimental protocol
Nitrous oxide was discontinued after animal preparation and the
piglets were ventilated with 30% oxygen in air. After 30 min, baseline
values were obtained. The piglets were then randomized into three
groups. The ¢rst group, denoted VF5, was subjected to 5 min of
VF followed by 5 min of closed-chest CPR. The second group, de-
noted VF2, was subjected to 2 min of VF followed by 5 min of closed-
chest CPR. Six animals served as a control group with no further
interventions. In the two intervention groups, VF was induced with
a brief alternating current shock of 40^60 V administered by two
subcutaneous needles. Cardiac arrest was de¢ned as VF on the
ECG and the loss of arterial pulsation. Ventilation was stopped at
the same time. After the non-intervention period (2 or 5 min) external
thoracic compressions (80/min) were applied in the intervention
groups and ventilation was resumed with 100% oxygen. A bolus in-
jection of 20 Wg/kg epinephrine was administered through the right
atrial catheter 4 min after the commencement of CPR. External de-
¢brillatory shocks of 200 J were applied 1 min after epinephrine
administration (5 min of closed-chest CPR). De¢brillatory shocks
were applied over a maximum period of 5 min. CPR was discontinued
if ROSC was not achieved during this time. ROSC was de¢ned as a
pulsatile rhythm with a systolic aortic blood pressure s 60 mm Hg
maintained for at least 10 min. After 5 min of spontaneous circulation
the FIO2 was reset to 0.3. Blood samples were collected from the
jugular bulb catheter and the pulmonary artery catheter at baseline,
5 min after ROSC, 30 min after ROSC and every 30 min thereafter,
up to 6 h of spontaneous circulation. The plasma samples were kept
frozen at 370‡C until analysis.
2.4. Radioimmunoassay of 8-iso-PGF2K
The plasma samples were analyzed for 8-iso-PGF2K by a radioim-
Fig. 1. Schematic diagram of endogenous formation of 8-iso-PGF2K via free radical and 15-keto-dihydro-PGF2K via cyclooxygenase catalyzed
oxidation of arachidonic acid.
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munoassay (RIA) at our laboratory as described elsewhere [19]. In
brief, unextracted plasma samples were used in the assay. The cross-
reactivity of the 8-iso-PGF2K antibody with 15-keto-13,14-dihydro-8-
iso-PGF2K, 8-iso-PGF2L, PGF2K, 15-keto-PGF2K, 15-keto-13,14-dihy-
dro-PGF2K, TXB2, 11L-PGF2K, 9L-PGF2K and 8-iso-PGF3K, respec-
tively was 1.7, 9.8, 1.1, 0.01, 0.01, 0.1, 0.03, 1.8 and 0.6%. The detec-
tion limit of the assay was about 23 pmol/l.
2.5. Radioimmunoassay of 15-K-DH-PGF2K
The plasma samples were analyzed for 15-K-DH-PGF2K by a RIA
at our laboratory as described elsewhere [18]. In brief, unextract-
ed plasma samples were used in the assay. The cross-reactivity of
the antibody with PGF2K, 15-keto-PGF2K, PGE2, 15-keto-13,14-di-
hydro-PGE2, 8-iso-15-keto-13,14-dihydro-PGF2K, 11L-PGF2K, 9L-
PGF2K, TXB2 and 8-iso-PGF3K was 0.02, 0.43, 6 0.001, 0.5, 1.7,
6 0.001, 6 0.001, 6 0.001, 0.01%, respectively. The detection limit
was about 45 pmol/l.
2.6. Statistical analysis
All data are expressed as mean þ S.E.M. Repeated measures of
ANOVAs were performed to test di¡erences between treatment
groups over time periods. For the ANOVAs that were statistically
signi¢cant, the Bonferroni-Dunn multiple comparison procedure was
performed to determine how the mean responses among the treatment
Fig. 2. Mixed venous plasma levels of 8-iso-PGF2K at baseline and after ROSC (upper panel). Jugular bulb plasma levels of 8-iso-PGF2K
at baseline and after ROSC (lower panel). 8, group VF5; F, group VF2; and R, control group. *, signi¢cant di¡erence versus baseline;
and 3, signi¢cant di¡erence between group VF5 versus other groups. Values are expressed as means þ S.E.M.
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groups di¡ered. To determine di¡erences within each group over time
paired t-tests were used. P values of 6 0.05 were considered to in-
dicate a signi¢cant di¡erence.
3. Results
3.1. Oxidative injury as determined by plasma 8-iso-PGF2K
No di¡erences in baseline levels of mixed venous or jugular
bulb 8-iso-PGF2K were observed between the groups. 8-iso-
PGF2K in the mixed venous plasma increased signi¢cantly in
both intervention groups within 5 min after ROSC (P = 0.005
and P = 0.014 for group VF2 and VF5, respectively, as com-
pared to the baseline, Fig. 2, upper panel). Mixed venous
levels of 8-iso-PGF2K returned to baseline within 30 min in
the VF2 group and within 60 min in the VF5 group and
remained unchanged during the remainder of the study.
The group subjected to 5 min of ventricular ¢brillation
showed a signi¢cant increase in 8-iso-PGF2K levels in the jug-
ular bulb plasma, with a maximum level four-fold higher than
baseline during a period of 30 min after ROSC (P = 0.008 vs.
Fig. 3. Mixed venous plasma levels of 15-keto-dihydro-PGF2K at baseline and after ROSC (upper panel). Jugular bulb plasma levels of 15-
keto-dihydro-PGF2K at baseline and after ROSC (lower panel). 8, group VF5; F, group VF2; and R, control group. *, signi¢cant di¡erence
versus baseline; 3, signi¢cant di¡erence between intervention groups versus control group. Values are expressed as means þ S.E.M.
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baseline, Fig. 2, lower panel). Thereafter, jugular bulb plasma
8-iso-PGF2K decreased gradually and reached the baseline
within 150 min. In the VF2 group, a two-fold increase in
jugular bulb 8-iso-PGF2K was recorded at 5 min after
ROSC (P = 0.008 vs. baseline), which returned to the baseline
within 30 min. No increase in jugular bulb or mixed venous
plasma level of 8-iso-PGF2K was recorded in the control
group. During a period of 120 min after ROSC, jugular
bulb plasma 8-iso-PGF2K was signi¢cantly greater in the
VF5 group as compared to the VF2 and the control group
(P6 0.0001, VF5 vs. VF2; P = 0.0003, VF5 vs. control).
3.2. In£ammatory response as determined by plasma
15-keto-dihydro-PGF2K
Baseline levels of 15-keto-dihydro-PGF2K in the jugular
bulb or mixed venous plasma did not di¡er between the
groups. After ROSC, mixed venous levels of 15-keto-dihy-
dro-PGF2K increased signi¢cantly in both intervention groups
(P = 0.022 and P = 0.005 for group VF2 and VF5, respectively,
as compared to the baseline, Fig. 3, upper panel). It decreased
thereafter to reach the baseline within 120 min and remained
unchanged during the remainder of the study. During the
initial 120 min after ROSC, mixed venous plasma 15-keto-
dihydro-PGF2K was signi¢cantly higher in the intervention
groups as compared to the control group (P = 0.0003, VF2
vs. control; P6 0.0001, VF5 vs. control).
In the group subjected to 5 min of VF, a four-fold increase
in jugular bulb 15-keto-dihydro-PGF2K was recorded at 5 and
30 min after ROSC, as compared to the baseline (P = 0.0302,
30 min vs. baseline, Fig. 3, lower panel). Thereafter, jugular
bulb 15-keto-dihydro-PGF2K decreased gradually and reached
baseline after 240 min. A similar pattern was observed in
the VF2 group, with a three-fold increase in jugular bulb
15-keto-dihydro-PGF2K as compared to baseline at 30 min
after ROSC (P = 0.007). A transient increase in jugular bulb
15-keto-dihydro-PGF2K was also recorded in the control
group, but not to the same magnitude as in the intervention
groups (P = 0.0001, VF2 vs. control and P6 0.0013, VF5 vs.
control).
4. Discussion
To our knowledge, the present study is the ¢rst to report an
increase both in isoprostane and prostaglandin formation
after resuscitation from cardiac arrest. It clearly demonstrates
that both 8-iso-PGF2K and 15-keto-dihydro-PGF2K levels in
the jugular bulb plasma are signi¢cantly increased during the
post-resuscitation period, indicating an association between
cerebral ischemia ^ during cardiac arrest and CPR ^ and
the oxidative injury and in£ammatory response after ROSC.
Furthermore, prolonged cardiac arrest is shown to increase
the magnitude of oxidative reperfusion injury and in£amma-
tory response in the brain, as determined by jugular bulb
levels of 8-iso-PGF2K and 15-keto-dihydro-PGF2K. These
also indicate that both free radical and cyclooxygenase cata-
lyzed oxidation of arachidonic acid occurs during reperfusion
injury.
The rationale for choosing 2 and 5 min of VF in this study
is the evidence available for an association between the dura-
tion of circulatory arrest and CPR and the degree of cerebral
dysfunction after resuscitation from cardiac arrest [21,22].
Hence, in the group subjected to 5 min of VF greater neuro-
logic damage may be expected, as compared to 2 min of VF
or the control group. It is, therefore, conceivable that in-
creased jugular bulb levels of 8-iso-PGF2K and 15-keto-dihy-
dro-PGF2K recorded in the VF5 group are associated with
increased lipid peroxidation in the brain and worse neurologic
outcome. This ¢nding indicates that jugular bulb measure-
ments of 8-iso-PGF2K and 15-keto-dihydro-PGF2K may be
used as a possible method for predicting lipid peroxidation
mediated neurologic outcome in patients resuscitated from
cardiac arrest.
Another important observation was the extended period
during which high isoprostane levels were measured in jugular
bulb plasma samples (up to 120 min after ROSC). This ob-
servation is consistent with results from previous histopatho-
logical and physiological studies of post-ischemic progression
of neuronal damage [23^25], supporting the theory of a de-
layed onset of morphological and metabolic neuronal distur-
bances after anoxia.
A transient increase in mixed venous plasma 8-iso-PGF2K
after ROSC may be attributed to a systemic reperfusion oxi-
dative damage. Interestingly, mixed venous 8-iso-PGF2K did
not increase to the same magnitude as in the jugular bulb
plasma. Furthermore, because under normal conditions ap-
proximately 15% of the mixed venous return originates from
the brain, it is conceivable that the increase in mixed venous
8-iso-PGF2K is in part caused by the biosynthesis and release
of this isoprostane from the brain tissue. However, mixed
venous 8-iso-PGF2K decreased to baseline soon after the ini-
tial increase at 5 min, while jugular bulb levels of 8-iso-PGF2K
remained high until 150 min. Considering the remarkably
short plasma half-life of 8-iso-PGF2K [26], the most credible
explanation for the di¡erence in jugular bulb and mixed ve-
nous 8-iso-PGF2K levels is a prolonged and signi¢cantly great-
er post-ischemic free radical catalyzed lipid peroxidation in
cerebral tissue, as compared to the whole body.
In conclusion, measurements of 8-iso-PGF2K and 15-keto-
dihydro-PGF2K in the jugular bulb plasma can be served as
biomarkers of cerebral oxidative injury and in£ammatory re-
sponse after resuscitation from cardiac arrest. This also opens
excellent possibilities to study the role of free radical and
cyclooxygenase mediated lipid peroxidation in reperfusion in-
jury.
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